The FDA approved a label update for axicabtagene ciloleucel (Yescarta), removing a prior contraindication for treating patients with primary CNS lymphoma. Dana‑Farber investigators contributed data that supported safety and efficacy in this population, prompting the change. The revision broadens access to a CD19‑directed CAR‑T therapy for a previously excluded high‑need neurological oncology group and may change referral patterns between neuro‑oncology and cellular‑therapy centers. Clinicians will need to integrate new safety monitoring recommendations into CAR‑T programs treating CNS disease.